Legend Biotech Corporation, the majority-owned cell therapy arm of Hong Kong-based life science firm Genscript Biotech, has entered into an agreement to raise about $150.5 million, according to a regulatory filing with the Hong Kong Stock Exchange (HKEX) on March 31.
Continue reading this premium story with a subscription to DealStreetAsia.Subscribe
Already a Subscriber? Log in
Contact us for corporate subscriptions at email@example.com